INTRODUCTION {#mxy001s1}
============

Globally, considering pretrial detainees, remand prisoners, or individuals convicted and sentenced, more than 10 million people are held in prison. In 2015, just greater than 600,000 persons were being held in prison of the European Union (EU)/European Economic Area (EEA), with considerable variation between countries. The imprisonment rate per 100,000 population varied from 21.3 in Liechtenstein followed by 53 in the Netherlands to 277.7 in Lithuania ([@mxy001C1], [@mxy001C2]). When considering the whole European region, the median age of the prison population was 35 years, the median proportion of female inmates was 5%, and the average length of stay was 7 months ([@mxy001C1], [@mxy001C2]).

People in prison have multiple complex needs, including health needs (i.e., physical, mental, and substance misuse needs) and social needs (e.g., homelessness, joblessness, lack of education, indebtedness), and may come from vulnerable, marginalized, or underserved populations in the community, including migrant, ethnic minority, and other socially excluded groups. ([@mxy001C2]--[@mxy001C4]). This complex mix of socioeconomic determinants contributes disproportionately to wider health inequalities in the prison population. In addition, an international review of studies on drug use in prison found that 10%--61% of men and 30%--69% of women prisoners were dependent on or had used illicit drugs in the month before entering prison ([@mxy001C5]). "Because of the illegality of the drugs market and the high price of drugs,...the more problematic forms of drug use are often accompanied by criminal behavior and an increased risk of imprisonment" ([@mxy001C6], p. 3). Problem drug--use patterns, including injecting drug use, are common among prison populations in European countries ([@mxy001C7]).

Compared with the general population, people in prison are characterized by a higher prevalence of infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV); other sexually transmitted infections (STIs); and tuberculosis (TB) ([@mxy001C8], [@mxy001C9]), and are exposed to increased risk of acquiring such infections during the incarceration period ([@mxy001C10]). "The increased prevalence of...people in prison return to their communities" ([@mxy001C6], p. 3) after incarceration ([@mxy001C2]). Individual influences such as education level, high-risk behaviors, societal factors, environmental factors such as high inmate density (aggravated by overcrowding in some EU/EEA correctional facilities), diet, and hygiene have been shown to create a conducive environment for the concentration and transmission of diseases in prison ([@mxy001C3], [@mxy001C10]). Substandard health care provision and large proportions of infected people in prison unaware of their status ([@mxy001C11]--[@mxy001C13]) add to the toll, with obvious implications for public health.

On the other hand, the prison setting may offer a great opportunity for primary, secondary, and tertiary prevention if coupled with adequate linkage to care ([@mxy001C10], [@mxy001C14]). Tailored and equitable health care provision in prisons has the potential to reach vulnerable and underserved groups of the population and address their complex needs. According to the model of the community dividend ([@mxy001C15]), the effect of successful health interventions in prison settings may benefit not only the single individual and the prison population but is likely to largely accrue in the wider community ([@mxy001C4], [@mxy001C16]). Active case finding, defined by the World Health Organization as "the systematic identification of people with a suspected disease, in a predetermined target group, using tests, examinations or other procedures that can be applied rapidly" ([@mxy001C17]), is certainly one such intervention. "Active case finding may be offered at different timings in the prison setting, i.e., at entry \[reception screening\], during imprisonment \[at regular intervals or ad hoc according to need/risks identified\], or \[in preparation for\] release. While active case finding at entry and during imprisonment is mostly targeted to prevent disease spread within the prison population, active case finding at release is a key measure to prevent disease spread into the community \[([@mxy001C18])\]" ([@mxy001C6], p. 4). In any instance, active case finding should be associated with access to appropriate treatment and care programs. STIs, TB, and HCV (with the new generation of directly active antivirals) are curable; therefore, prisons could represent crucial places to reach underserved patients and cure their infection, thus influencing both the single patient's clinical outcome and the risk of disease transmission inside prisons and in the wider community after release. Although HIV and chronic hepatitis B are not curable, treatment is available. Early treatment of HIV infection has been associated with individual patient clinical benefits and a dramatic decrease in the risk of transmission to sexual partners; this is the concept of "treatment as prevention" ([@mxy001C19]--[@mxy001C21]).

However, large heterogeneity exists among EU/EEA prison settings regarding conditions, populations, communicable disease burden, existing prevention and care policies, and, particularly, active case--finding interventions ([@mxy001C22], [@mxy001C23]). In this study, we assessed the effect of and identified service delivery models for active case finding for communicable diseases in prison settings in the EU/EEA. We collected, synthesized, and appraised the available evidence from Europe and selected high-income countries on the modalities and effectiveness of active case--finding interventions in prison settings. This systematic review is part of a larger joint project by the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drug and Drug Addiction, which aims to produce a European guidance document on prevention and control of communicable diseases in prison settings in the EU/EEA. More details on the findings from this systematic review are presented in a technical report published elsewhere ([@mxy001C6]).

METHODS {#mxy001s2}
=======

We performed a systematic review of the literature following international methodology and reporting standards ([@mxy001C24], [@mxy001C25]), including peer-reviewed and gray literature, to gather existing evidence on the implementation modalities and effectiveness of active case finding in prison settings at prisoners' entrance and during their stay. We defined prison settings as prisons, jails, and other custodial settings functioning as prison (excluding migrant centers and police detention rooms); prison population was defined as all adult individuals (age ≥18 years) held in correctional facilities where a state holds people deprived of their liberty, including, when and where applicable, prison staff ([Web Appendix 1, Web Table 1](#sup1){ref-type="supplementary-material"}, available at <https://academic.oup.com/aje>).

According to the study protocol, we searched PubMed, Embase, and Cochrane Library databases for relevant hits on February 4, 2016, using a combination of search strings ([Web Appendix 2](#sup1){ref-type="supplementary-material"}) covering the project's broader research area. In brief, the search strings covered the following facets, with no language limit: prison settings; active case finding. Possible outcomes and communicable diseases were not included in the search terms. The following time limits were applied: 1990 onward in PubMed and Embase, and 1980 onward in the Cochrane Library database. The literature search was further limited during the title and abstract screening phase to include only literature from EU/EEA countries, EU candidate countries (i.e., Albania, Bosnia-Herzegovina, Montenegro, Serbia, Turkey), and other Westernized countries (i.e., Australia, Canada, New Zealand, Switzerland, and the United States). Articles from these non--EU/EEA countries were included to broaden the evidence base.

We captured all retrieved hits in an EndNote library (Clarivate Analytics, Philadelphia, PA) and performed deduplication by using the software built-in tool followed by a manual round. We screened the articles by title and abstract, and, if deemed possibly relevant, by reading the full text of the articles. Further scrutiny of the article during the extraction phase could have led to exclusion. Inclusion and exclusion criteria were predefined and covered the following domains: study design or type, study quality, study population, geographic area, and outcomes of interest ([Web Appendix 2, Web Table 2](#sup1){ref-type="supplementary-material"}). High-quality meta-analyses or systematic reviews were included in case they matched the review objectives. If not, the relevant individual articles were assessed.

We used standard evidence based medicine checklists to assess the quality of included peer-reviewed articles and aimed to identify quality limitations. For this review, we used the National Institute for Health and Clinical Excellence checklists, which are available for the following study designs: systematic reviews and meta-analyses, randomized controlled trials, cohort studies, case-control studies, diagnostic accuracy studies, economic evaluations, and qualitative studies ([@mxy001C26]). For surveillance studies or other observational study designs, where no standard checklists are available, we performed the assessment based on relevant aspects of the existing National Institute for Health and Clinical Excellence checklists, supplemented with a set of questions for a specific study design ([Web Appendix 3](#sup1){ref-type="supplementary-material"}). For the studies included in the review, the level of evidence per individual article was determined based on the study design and risk of bias, following Grading of Recommendations Assessment, Development and Evaluation criteria.

To complement the evidence from the peer-reviewed literature, we searched for gray literature documents such as articles, abstracts, research reports, case studies, service models, and clinical protocols released by any EU/EEA country from 2005 onward that met a predefined set of inclusion and exclusion criteria adapted from the peer-reviewed literature ([Web Appendix 4, Web Table 3](#sup1){ref-type="supplementary-material"}). We searched a predefined list of websites ([Web Appendix 4](#sup1){ref-type="supplementary-material"}) in February 2016 using terms for prison settings (i.e., prison, jail, correctional, incarcerated). If this resulted in many hits, a more specific search was performed by combining the prison terms with terms such as "infectious diseases" or "screening" or "case finding." If a website was focused only on prison populations, only search terms related to infectious diseases and active case finding (see above) were used. In addition, expert input was obtained by a call for papers issued via Health without Barriers, the European Federation for prison health network (<http://www.hwbfederation.eu/>) between April and June 2016. Conference abstracts were checked for duplication with the included peer-reviewed literature and the full-text article was preferred. Conference abstracts and unpublished research reports focusing on the prison setting were included only if they contained sufficiently detailed information on methods and/or data sources or references.

We extracted from each of the included records all relevant information in a standardized evidence table, namely: reference (i.e., author, year, journal, country), study characteristics (i.e., study design, study period, follow-up, setting, study objective), study population, sample description (i.e., sample size, sex, age, risk groups), data sources and definitions, reviewer comments, limitations, level of evidence, and outcome. We considered the following outcomes of interest: uptake, positivity rate, effectiveness (i.e., change in number or percentage tested, change in prevalence or incidence, other), treatment initiation, cost-effectiveness, acceptability, feasibility, and accessibility. The selected case-finding intervention modalities were as follows: timing (i.e., at entry, during imprisonment, at release), offer (i.e., mandatory; opt-in, opt-out; client-initiated testing), target population (e.g., universal, targeted), and testing promotion (e.g., education, counseling). We defined opt-in testing as the active offer of testing to all eligible individuals (e.g., based on the identification of a specific risk factor) and the person chooses whether or not to have the test; opt-out testing was defined as when all eligible individuals (e.g., all individuals entering prison) are informed the test will be performed unless they actively refuse ([@mxy001C13]); client-initiated testing was defined as when the individual actively seeks testing on their own initiative. We analyzed the data by disease, testing modality, and outcome. For studies that did not clearly specify the modality of the testing offer, we assumed, based on the information available in the narrative, that testing was actively offered by health care staff (i.e., opt-in) to all individuals if not specified for a certain subgroup. Quality control measures were put in place, as reported in detail in the [Web Appendix 5](#sup1){ref-type="supplementary-material"}.

We analyzed the findings with respect to study descriptors (e.g., testing modalities, target population), study outcomes (e.g., uptake rates, positivity rate, effectiveness, secondary outcomes, barriers to testing), and study quality. We did not use summary measures to synthesize the results in consideration of the large heterogeneity between studies (e.g., study design, population group, intervention modalities).

RESULTS {#mxy001s3}
=======

Study characteristics {#mxy001s3a}
---------------------

We retrieved a total of 7,041 unique hits from the peer-reviewed literature search, 122 documents from the call for papers, and 22 from the websites search. On the basis of inclusion and exclusion criteria, we included 90 records: 63 from peer-reviewed literature, 26 from gray literature sources, and 1 systematic review, which contributed 16 studies ([@mxy001C13]) (Figures [1](#mxy001F1){ref-type="fig"} and [2](#mxy001F2){ref-type="fig"}). A total of 23 records provided data on viral hepatitis, 34 on HIV, 23 on STIs, and 27 on TB; no records were identified on other communicable diseases. Overall, most of the included peer-reviewed studies were conducted in the United States or other non--EU/EEA countries; only 14 records reported findings from the EU/EEA region.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart for the included peer-reviewed literature 1990--February 2016 (1980-February 2016 for the Cochrane Database). Some included records reported data on more than 1 disease. HIV, human immunodeficiency virus; STI, sexually transmitted infection; TB, tuberculosis.](mxy001f01){#mxy001F1}

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart for the included gray literature. Some included records reported data on more than 1 disease. HIV, human immunodeficiency virus; STI, sexually transmitted infection; TB, tuberculosis.](mxy001f02){#mxy001F2}

Quality of the studies {#mxy001s3b}
----------------------

The study quality was largely very low, with a few exceptions. For 8 studies, the level of evidence was classified as low ([@mxy001C27]--[@mxy001C34]); for additional 8, it was classified as moderate ([@mxy001C16], [@mxy001C35]--[@mxy001C41]) ([Web Appendix 6, Web Tables 4--13](#sup1){ref-type="supplementary-material"}).

Testing modalities {#mxy001s3c}
------------------

We retrieved 71 studies reporting data collection on testing initiatives in prison settings, covering HBV, HCV, chlamydia, gonorrhea, syphilis, trichomoniasis, active TB, and latent TB infection (LTBI) (Tables [1](#mxy001TB1){ref-type="table"}--[3](#mxy001TB3){ref-type="table"} and [Web Appendix 6, Web Tables 4--13](#sup1){ref-type="supplementary-material"}). Offering a test upon entry into prison was the modality most frequently reported for HCV (*n* = 9 studies) ([@mxy001C11], [@mxy001C13], [@mxy001C42]--[@mxy001C45]), HIV (*n* = 18 studies) ([@mxy001C13], [@mxy001C36], [@mxy001C42], [@mxy001C44], [@mxy001C46]--[@mxy001C53]), syphilis (*n* = 5 studies) ([@mxy001C43], [@mxy001C46], [@mxy001C54]--[@mxy001C56]), and active TB (*n* = 4 studies) ([@mxy001C57]--[@mxy001C59]). Testing offered at entry and regularly during stay was reported for HIV (*n* = 10 studies) ([@mxy001C43], [@mxy001C60]--[@mxy001C68]), HCV (*n* = 2 studies) ([@mxy001C63], [@mxy001C69]), active TB (*n* = 2 studies) ([@mxy001C70], [@mxy001C71]), and LTBI (*n* = 3 studies) ([@mxy001C71]--[@mxy001C73]). Testing for people while in prison was most commonly reported for HBV (*n* = 4 studies) ([@mxy001C61], [@mxy001C62], [@mxy001C74], [@mxy001C75]), chlamydia and gonorrhea (*n* = 5 studies) ([@mxy001C29], [@mxy001C30], [@mxy001C76]--[@mxy001C78]), and LTBI (*n* = 6 studies) ([@mxy001C61], [@mxy001C75], [@mxy001C79]--[@mxy001C82]). Testing at release was reported by 1 multidisease study ([@mxy001C83]) on mandatory testing and 2 additional studies reporting on HIV only ([@mxy001C44], [@mxy001C84]). Opt-out testing was only described in studies conducted outside the EU/EEA and exclusively as a modality for HIV active case finding ([@mxy001C13], [@mxy001C29]). Client-initiated testing was described as a complementary approach to opt-in offered during imprisonment for HIV ([@mxy001C47], [@mxy001C53]) or reported as comparator in a few additional studies investigating the effect of different testing modalities for HCV ([@mxy001C35], [@mxy001C45]), HIV ([@mxy001C13]), and STIs ([@mxy001C31], [@mxy001C85]--[@mxy001C89]). Table 1.Summary of Results of the Included Studies Reporting on Active Case Finding for Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus, 1990--February 2016^a^First Author, Year (Reference No.)RegionTesting ModalityHepatitis B VirusHepatitis C VirusHIVUptake, %Positivity Rate, %Positivity Rate of Newly Diagnosed Infections, %Uptake, %Positivity Rate, %Positivity Rate of Newly Diagnosed Infections, %Uptake, %Positivity Rate, %Positivity Rate of Newly Diagnosed Infections, %Foschi, 2015 ([@mxy001C43])EU/EEAAt entry; opt in91.56.691.59.8Gabbuti, 2015 (unpublished data^b^)EU/EEAAt entry; opt in95.08.182.328.2Rumble, 2015 (citing Horne, 2004) ([@mxy001C13])EU/EEAAt entry; opt in12.012.0Jacomet, 2016 ([@mxy001C44])EU/EEAAt entry; opt in91.30.60.389.94.72.091.30.30Kivimets, 2014 ([@mxy001C48])EU/EEAAt entry; opt in97.312.51.8Rumble, 2015 (citing Skipper, 2003) ([@mxy001C13])EU/EEAAt entry; opt in9.029.9Rumble, 2015 (citing Andrus, 1998) ([@mxy001C13])Non--EU/EEAAt entry; opt in65.00.9Arriola, 2001 ([@mxy001C46])Non--EU/EEAAt entry; opt inNR17.07.0Beckwith, 2015 ([@mxy001C42])Non--EU/EEAAt entry; opt in26.010.095.00.0Rumble, 2015 (citing Behrendt, 1994) ([@mxy001C13])Non--EU/EEAAt entry; opt in47.05.4Rumble, 2015 (citing Cotton, 1999) ([@mxy001C13])Non--EU/EEAAt entry; opt in71.02.5Rumble, 2015 (citing Hoxie 1990) ([@mxy001C13])Non--EU/EEAAt entry; opt in71.00.6Kassira, 2001 ([@mxy001C47])Non--EU/EEAAt entry; opt in39.03.3Kim, 2013 ([@mxy001C45])Non--EU/EEAAt entry; opt in80.725.4Kuncio, 2015 ([@mxy001C11])Non--EU/EEAAt entry; opt inNR57.0Rumble, 2015 (citing Liddicoat, 2006) ([@mxy001C13])Non EU/EEAAt entry; opt in73.00.3Macgowan, 2009 ([@mxy001C49])Non--EU/EEAAt entry; opt in6.01.30.8Pearson, 2014 ([@mxy001C36])Non--EU/EEAAt entry; opt in53.0NRRosen, 2009 ([@mxy001C53])Non--EU/EEAAt entry; opt in34.0NRShrestha, 2009 ([@mxy001C50])Non--EU/EEAAt entry; opt inNR2.41.3Spaulding, 2015 ([@mxy001C51])Non--EU/EEAAt entry; opt in38.41.1Rumble, 2015 (citing Strick, 2011) ([@mxy001C13])Non--EU/EEAAt entry; opt in72.0NR0.1Tartaro, 2013 ([@mxy001C52])Non--EU/EEAAt entry; opt in50.03.00.1Rumble, 2015 (citing Watkins, 2009) ([@mxy001C13])Non--EU/EEAAt entry; opt inNR24.8NR0.6Rumble, 2015 (citing Beckwith, 2010) ([@mxy001C13])Non--EU/EEAAt entry; opt outNRNR0.2Rumble, 2015 (citing Beckwith, 2011) ([@mxy001C13])Non--EU/EEAAt entry; opt out98.0NR0.1Rumble, 2015 (citing Kavasery, 2009a) ([@mxy001C13])Non--EU/EEAAt entry; opt out91.0NR0.0Rumble, 2015 (citing Kavasery, 2009b) ([@mxy001C13])Non--EU/EEAAt entry; opt out70.0NR0.8Rumble, 2015 (citing Spaulding, 2013) ([@mxy001C13])Non--EU/EEAAt entry; opt out64.0NR0.4Rumble, 2015 (citing Strick, 2011) ([@mxy001C13])Non--EU/EEAAt entry; opt out90.0NR0.1Babudieri, 2008 ([@mxy001C60])EU/EEAAt entry and stay63.510.8Babudieri, 2012 ([@mxy001C61])EU/EEAAt entry and stay56.35.6Babudieri, 2015 ([@mxy001C62])EU/EEAAt entry and stay83.83.9Foschi, 2015 ([@mxy001C43])EU/EEAAt entry and stay91.53.2Gallego, 2010 ([@mxy001C64])EU/EEAAt entry and stay82.59.9Khaw, 2007 ([@mxy001C69])EU/EEAAt entry and stay63.336.8Lugo, 2012 ([@mxy001C65])EU/EEAAt entry and stayNR10.9Marco, 2014 ([@mxy001C66])EU/EEAAt entry and stayNR1.0Monarca, 2002 ([@mxy001C67])EU/EEAAt entry and stayNR26.6Prestileo, 2006 ([@mxy001C68])EU/EEAAt entry and stayNR35.4Cocoros, 2014 ([@mxy001C63])Non--EU/EEAAt entry and stay21.920.526.40.8Babudieri, 2012 ([@mxy001C61])EU/EEADuring stay56.35.356.332.8Babudieri, 2015 ([@mxy001C62])EU/EEADuring stay83.84.783.817.6Bedoya, 2014 ([@mxy001C74])EU/EEADuring stayNR13.2Kivimets, 2014 ([@mxy001C48])EU/EEADuring stay96.00.1Sagnelli, 2012 ([@mxy001C75])EU/EEADuring stay65.34.464.622.867.43.8Jacomet, 2016 ([@mxy001C44])EU/EEAAt release4.20.0Sieck, 2011 ([@mxy001C83])Non--EU/EEAAt releaseNR0.5NR1.7NR0.1Simonsen, 2015 ([@mxy001C84])Non--EU/EEAAt release60.00.3[^1][^2][^3]Table 2.Summary of Results of the Included Studies Reporting on Active Case Finding for Sexually Transmitted Infections, 1990--February 2016^a^RegionReferenceTesting ModalityChlamydia/Gonorrhea/TrichomoniasisSyphilisUptake, %Chlamydia Positivity Rate, %Gonorrhea Positivity Rate, %Trichomoniasis Positivity Rate, %Uptake, %Positivity Rate, %EU/EEAFoschi, 2015 ([@mxy001C43])At entry; opt in65.83.6Non--EU/EEAArriola, 2001 ([@mxy001C46])At entry; opt inNR6.53.10NR2.0Non--EU/EEAFranklin, 2012 ([@mxy001C85])At entry; opt in100.06.40.9Non--EU/EEAHeimberger, 1993 ([@mxy001C54])At entry; opt in77.02.6Non--EU/EEAKahn, 2002 ([@mxy001C55])At entry; opt in76.06.0Non--EU/EEAMertz, 2002 ([@mxy001C90])At entry; opt in100.0NRNRNon--EU/EEARoth, 2011 ([@mxy001C88])At entry; opt inNR44.0Non--EU/EEASilberstein, 2000 ([@mxy001C56])At entry; opt in69.01.4Non--EU/EEACole, 2014 ([@mxy001C31])At entry; opt out78.12.57.6Non--EU/EEAShaikh, 2015 ([@mxy001C29])At entry; opt outNR9.31.3EU/EEABabudieri, 2012 ([@mxy001C61])During stay56.32.3EU/EEALopez-Corbeto, 2012 ([@mxy001C76])During stayNR11.0EU/EEASagnelli, 2012 ([@mxy001C75])During stay55.72.1EU/EEATorrez, 2010 ([@mxy001C78])During stay98.46.02.0Non--EU/EEABrown, 2014 ([@mxy001C30])During stayNR5.30.8Non--EU/EEANewman, 2003 ([@mxy001C77])During stay82.1NRNon--EU/EEAShaikh, 2015 ([@mxy001C29])During stayNR5.60.9Non--EU/EEASieck, 2011 ([@mxy001C83])At release37.60.60.05.5NR0.1[^4][^5]Table 3.Summary of Results of the Included Studies Reporting on Active Case Finding for Tuberculosis, 1990--February 2016^a^RegionReferenceTesting ModalityActive TuberculosisLatent Tuberculosis InfectionsUptake, %Positivity Rate, %Uptake, %Positivity Rate, %EU/EEAFoschi, 2015 ([@mxy001C43])At entry; opt in81.49.8EU/EEAGarcía-Guerrero, 2010 ([@mxy001C92])At entry; opt in90.250.4EU/EEAMartin, 2001 ([@mxy001C57])At entry; opt in82.50.282.541.3EU/EEARuiz-Rodríguez, 2010 ([@mxy001C81])At entry; opt in11.6NREU/EEASolé, 2010 ([@mxy001C93])At entry; opt in100.049.3EU/EEABös, 2011 (unpublished data)At entry; opt in100.0NRNon--EU/EEABock, 2001 ([@mxy001C104])At entry; opt in75.07.2Non--EU/EEAPuisis, 1996 ([@mxy001C58])At entry; opt in75.00.1Non--EU/EEARitter, 2012 ([@mxy001C59])At entry; opt in77.32.3EU/EEAAndreev, 2011 ([@mxy001C70])Entry and stayNR0.3EU/EEAVera-Remartinez, 2014 ([@mxy001C73])Entry and stay100.044.9Non--EU/EEABock, 1999 ([@mxy001C72])Entry and stayNR18.0Non--EU/EEAMiller, 2006 ([@mxy001C71])Entry and stayNR0.03NR0.9EU/EEABabudieri, 2012 ([@mxy001C61])During stayNR21.80EU/EEAFernandez-Prieto, 2010 ([@mxy001C79])During stay92.621.8EU/EEAGabbuti, 2010 ([@mxy001C80])During stay15.441.6EU/EEARuiz-Rodríguez, 2010 ([@mxy001C81])During stay100.019.3EU/EEASagnelli, 2012 ([@mxy001C75])During stay42.817.2EU/EEAVera, 2010 ([@mxy001C82])During stay90.250.4Non--EU/EEAKiter, 2003 ([@mxy001C100])During stay99.80.4[^6][^7]

Target population {#mxy001s3d}
-----------------

Overall, most of the studies reported on universal offering of testing to all people in prison, particularly if testing was performed at entry ([Web Appendix 6, Web Tables 4--12](#sup1){ref-type="supplementary-material"}), with some disease-specific variations. Furthermore, testing for HCV was considered for individuals with no previous HCV diagnosis ([@mxy001C43]) in only 1 study in men only, which was included in the review by Rumble et al. ([@mxy001C13]), and in 2 studies of high-risk individuals (e.g., people who inject drugs; people living with HIV) ([@mxy001C11], [@mxy001C46]). HCV testing targeting people who inject drugs was also explored in several cost-effectiveness studies performed in the United Kingdom that compared different modalities of test offers for that group ([@mxy001C32], [@mxy001C37]--[@mxy001C39]) and in a recent cost-effectiveness analysis from the United States ([@mxy001C16]) in which targeted testing was compared with universal testing. Testing for HIV was almost always reported to be universal, with 2 exceptions: 1 study ([@mxy001C51]) in which people living with HIV and mentally incompetent individuals were excluded, and 1 ([@mxy001C68]) that focused on people who inject drugs. Finally, screening for pregnant women and newborns in prison settings was reported on in 1 cost-effectiveness study ([@mxy001C41]).

Whereas testing for syphilis was universal in all retrieved studies, testing for chlamydia, gonorrhea, and trichomoniasis was commonly targeted to women only ([@mxy001C31], [@mxy001C77], [@mxy001C86], [@mxy001C90]), was symptom based for men or women ([@mxy001C86], [@mxy001C88]), or targeted at young individuals, more frequently men, variably defined as younger than 25, or 30 or 35 years old ([@mxy001C78], [@mxy001C87]). In 2 cost-effectiveness studies from outside the EU/EEA ([@mxy001C89], [@mxy001C91]), various targeted testing approaches were compared, including symptom-based, universal, and age-based testing.

Active TB case finding was universal in all retrieved studies. On the other hand, LTBI testing was performed among random samples of the prison population in 2 studies ([@mxy001C82], [@mxy001C92]) or among people with no history of TB ([@mxy001C57]), or among foreign-born individuals ([@mxy001C93]). In 2 surveys, 1 from outside the EU/EEA ([@mxy001C94]) and 1 covering the countries in the European region ([@mxy001C95]), investigators reported that LTBI testing among prison staff was most frequently conducted yearly (approximately half of the responding institutions or countries in both studies).

Summary of key study findings {#mxy001s3e}
-----------------------------

### Uptake of testing initiatives {#mxy001s3e_1}

The proportion of the eligible individuals undergoing testing (uptake) was reported by most of the studies in which active case finding initiatives in prison settings were reported, with some exceptions ([@mxy001C11], [@mxy001C13], [@mxy001C29], [@mxy001C30], [@mxy001C46], [@mxy001C50], [@mxy001C61], [@mxy001C65]--[@mxy001C68], [@mxy001C72], [@mxy001C74], [@mxy001C76], [@mxy001C83]). The uptake varied considerably across diseases and testing modalities, with no clear patterns (Tables [1](#mxy001TB1){ref-type="table"}--[3](#mxy001TB3){ref-type="table"}, Figure [3](#mxy001F3){ref-type="fig"}). Testing at entry was the modality resulting in higher uptake ranges; however, no comparative studies were identified that reported statistically significant differences. In general, older studies, including a few of those reported by Rumble et al. ([@mxy001C13], [@mxy001C44]), described lower uptake rates for HCV and HIV compared with studies from 2005 onward.

![Testing uptake rates by disease, testing modality, and geographic region. A) Bloodborne viruses (i.e., hepatitis B virus, hepatitis C virus, human immunodeficiency virus). B) Sexually transmitted diseases (i.e., chlamydia; gonorrhea; syphilis, trichomoniasis). C) Tuberculosis (active and latent tuberculosis infection). Circles indicate European Union /European Economic Area countries; triangles indicate Non--European Union/European Economic Area countries. InE, opt-in at entry; InE/S, opt-in at entry and during stay; InS, opt-in during stay; OutE, opt-out at entry; R, at release.](mxy001f03){#mxy001F3}

### Positivity rate {#mxy001s3e_2}

Overall, regardless of active case finding modalities, applying active case finding for bloodborne viruses (BBVs) in correctional facilities in the EU/EEA resulted in positivity rates of 0.6%--13.2% for HBV, 4.7%--36.8% for HCV, and 0.3%--26.6% for HIV (Table [1](#mxy001TB1){ref-type="table"} and [Web Appendix 6, Web Tables 5--7](#sup1){ref-type="supplementary-material"}). Newly diagnosed infection rates were reported to be 50% for HBV, 2% for HCV, and 0% for HIV in a French study ([@mxy001C45]). Rates of 1.8% of new HIV infections detected at entry and 0.06% during prison stay among previously HIV-negative individuals were reported in another study ([@mxy001C49]).

Positivity rates for STIs were reported in very few studies conducted in the EU/EEA, resulting in very limited geographic coverage. For chlamydia, gonorrhea, and syphilis, positivity rates were 6%--11%, 0.2%, and 2.1%--3.6%, respectively, in Spain and Italy. As a comparison, positivity rates ranged from 0.6% to 7.6% for chlamydia, from 0% to 3.1% for gonorrhea, and from 0.1% to 6% for syphilis in non--EU/EEA studies (Table [2](#mxy001TB2){ref-type="table"} and [Web Appendix 6, Web Tables 8--10](#sup1){ref-type="supplementary-material"}).

Positivity rates for active TB in the EU/EEA ranged between 0.12% and 0.3%, whereas applying LTBI active case findings resulted in a tuberculin skin test positivity rate ranging from 9.8% to 50.4% (Table [3](#mxy001TB3){ref-type="table"} and [Web Appendix 6, Web Tables 11--12](#sup1){ref-type="supplementary-material"}).

### Effectiveness and cost-effectiveness of testing modalities {#mxy001s3e_3}

In 5 studies, all from non--EU/EEA settings, researchers investigated the effectiveness of active case finding initiatives in prison settings by comparing the positivity rate with the prevalence of infection resulting from seroprevalence studies conducted on the same population. Kuncio et al. ([@mxy001C11]) estimated that targeted testing modality for HCV among high-risk individuals failed to detect up to 76% of HCV-infected individuals entering prison. In 3 similar, and fairly old, studies included in Rumble et al. ([@mxy001C13]), researchers found the proportion of undetected HIV cases with the opt-in testing modality ranged from 26% to 56%. Finally, authors of a more recent study ([@mxy001C12]) estimated that routine opt-in active case findings failed to detect up to 90% of previously undiagnosed HIV cases on entry to prison.

Targeted versus universal testing was investigated in several cost-effectiveness studies for HCV (1 study) and STIs (3 studies) ([Web Appendix 6, Web Tables 13](#sup1){ref-type="supplementary-material"}). In a recent cost-effectiveness analysis from the United States ([@mxy001C16]), HCV case finding was explored when direct active antiviral drugs were available. Universal testing was compared with targeted testing. The findings pointed to universal opt-out testing as being highly cost-effective with a 10-year horizon. In 2 cost-effectiveness studies from the United States ([@mxy001C89], [@mxy001C91]), age-based testing for chlamydia and gonorrhea was compared with universal or client-initiated testing (men only). Age-based targeted testing was found more likely to be cost-effective from both the health care and the prison perspectives. Sex-based testing was assessed in a US study ([@mxy001C96]); the researchers showed that universal active case finding for chlamydia was likely to be cost-saving for female detainees only.

### Interventions to increase uptake {#mxy001s3e_4}

Relatively few studies investigated the effect of different active case finding interventions to increase testing uptake in prison settings. Most (*n* = 9 studies) were focused on HIV active case finding ([@mxy001C13], [@mxy001C28], [@mxy001C36], [@mxy001C46], [@mxy001C62], [@mxy001C75], [@mxy001C97]), 5 on viral hepatitis ([@mxy001C27], [@mxy001C35], [@mxy001C45], [@mxy001C62], [@mxy001C75]), 4 on chlamydia and gonorrhea ([@mxy001C29], [@mxy001C31], [@mxy001C86], [@mxy001C87]), 1 each on syphilis ([@mxy001C75]) and trichomoniasis ([@mxy001C88]), 2 on TB ([@mxy001C58], [@mxy001C98]), and 2 involved a multidisease approach ([@mxy001C62], [@mxy001C75]) ([Web Appendix 6, Web Tables 5--12](#sup1){ref-type="supplementary-material"}).

In total, 9 studies investigated the effect of different test modalities on testing uptake; however, either no test of significance or no statistically significant results were reported for any of the studies. HIV was addressed in 3 studies ([@mxy001C13]), HCV in 1 ([@mxy001C45]), chlamydia and gonorrhea in 4 ([@mxy001C29], [@mxy001C31], [@mxy001C86], [@mxy001C87]), and trichomoniasis in 1 ([@mxy001C88]). None of these studies were performed in the EU/EEA. In 7 studies, opt-in testing at entry was compared with client-initiated testing. In all cases, the opt-in testing modality resulted in higher uptake rates across diseases ([@mxy001C13], [@mxy001C31], [@mxy001C45], [@mxy001C86]--[@mxy001C88]). Kim et al. ([@mxy001C46]) reported that patients with HCV detected through active case finding were twice as likely to be asymptomatic as compared with those detected through client-initiated testing (relative risk = 2.0; *P* = 0.09). In 3 studies, the effect of opt-out strategies was compared with opt-in testing. The findings were convergent and opt-out resulted in an increased uptake rate irrespective of the target disease ([@mxy001C13], [@mxy001C29]). However, a recent non--EU/EEA survey ([@mxy001C99]) revealed that more than 50% of the respondents participating in an opt-out testing program inaccurately reported that HIV testing in prison was mandatory.

The influence of educational interventions, including peer-education programs, on test uptake for HIV was investigated in 5 studies ([@mxy001C28], [@mxy001C36], [@mxy001C46], [@mxy001C62], [@mxy001C75]). Of these, 2 also included HBV and HCV ([@mxy001C62], [@mxy001C76]), 2 also included STIs ([@mxy001C46], [@mxy001C75]), and 1 study also included TB ([@mxy001C75]). An increase in testing uptake for all covered diseases after the introduction of an education intervention was reported in 4 studies, of which 2 were performed in the EU/EEA. Statistical analysis was performed only in 1 study and showed a significant increase of testing uptake ([@mxy001C28]). In an additional study, also conducted in a non--EU/EEA country, an intervention targeting staff rather than people living in prison was described; there was no statistically significant difference in the uptake of testing for HIV after the implementation of an education intervention ([@mxy001C36]).

In 5 studies, 2 of which were from the EU/EEA, the effect of different testing methods were investigated on testing uptake for HCV ([@mxy001C27], [@mxy001C35]), HIV ([@mxy001C97]), and TB ([@mxy001C58], [@mxy001C98]). In general, an increased uptake of testing for BBVs was observed when venipuncture sample collection was complemented by other approaches, such as dried blood spot and oral tests. However, no statistical test of significance was reported. Similarly, the introduction of rapid diagnostic tools such as chest radiograph resulted in the increased detection rate of TB and decreased time to isolation of an infected person.

### Other outcomes {#mxy001s3e_5}

In a few studies, hardly any of which were conducted in the EU/EEA, researchers presented findings on other relevant health outcomes, such as result notification rate and treatment initiation rate ([Web Appendix 6, Web Tables 4--12](#sup1){ref-type="supplementary-material"}). Testing-results notification was mainly reported for HIV, and this frequently was high as 100% at least for HIV-positive individuals ([@mxy001C13], [@mxy001C42], [@mxy001C49], [@mxy001C84]). In 15 studies, researchers reported on treatment initiation after diagnosis for HIV ([@mxy001C46], [@mxy001C60], [@mxy001C64], [@mxy001C68]), STIs ([@mxy001C31], [@mxy001C46], [@mxy001C54], [@mxy001C56], [@mxy001C85], [@mxy001C90]), and TB ([@mxy001C57], [@mxy001C70]--[@mxy001C72], [@mxy001C100]). The reported rates were variable (23%--100%), with treatment rates for LTBI being at the lower end of the range (23%--58%), whereas treatment ranges for active TB were higher (87%--100%). Linkage to care after release for HIV-positive patients was reported in 2 studies ([@mxy001C42], [@mxy001C84]).

### Acceptance, preferences, and barriers to testing {#mxy001s3e_6}

Testing acceptance and barriers were investigated in 15 studies ([@mxy001C30], [@mxy001C42], [@mxy001C44], [@mxy001C45], [@mxy001C52], [@mxy001C55], [@mxy001C57], [@mxy001C59], [@mxy001C69], [@mxy001C84], [@mxy001C98], [@mxy001C101]--[@mxy001C104]) and 1 systematic review ([@mxy001C13]) covering all target diseases. Sudden release and mobility within the prison system were cited in several studies as key factors hindering testing ([@mxy001C42], [@mxy001C44], [@mxy001C52], [@mxy001C57], [@mxy001C59], [@mxy001C98], [@mxy001C104]). This was of particular relevance for the completion of testing for LTBI, because of the lag time of the most common first-line testing and the need for a second visit (i.e., tuberculin skin test). Among personal barriers to testing, not perceiving oneself at risk ([@mxy001C13], [@mxy001C30], [@mxy001C52], [@mxy001C101], [@mxy001C103]) and having been tested already ([@mxy001C13], [@mxy001C42], [@mxy001C84], [@mxy001C98], [@mxy001C101], [@mxy001C102], [@mxy001C105]) were the main reasons for refusal. In studies that focused on testing for BBVs, researchers also reported as important barriers lack of awareness; fear of disease and of testing procedures ([@mxy001C13], [@mxy001C52], [@mxy001C69], [@mxy001C84], [@mxy001C103]), including fear of needles ([@mxy001C13], [@mxy001C44]); communication challenges ([@mxy001C42], [@mxy001C44]); and concern about confidentiality and stigma ([@mxy001C13], [@mxy001C52], [@mxy001C69], [@mxy001C103]). Finally, lack of trust in the institution was mentioned by some study authors as a reason testing was refused ([@mxy001C44], [@mxy001C52], [@mxy001C101]). Institutional barriers such as inconvenience of testing time, inadequate testing or counselling procedure, and lack of staff were also reported in a few studies as relevant factors ([@mxy001C13], [@mxy001C45], [@mxy001C52], [@mxy001C69]).

DISCUSSION {#mxy001s4}
==========

The aim of this study was to describe and assess the value of active case finding initiatives for communicable diseases in prison settings in the EU/EEA. To our knowledge, our study is the first attempt to provide a comprehensive and systematic overview on active case finding as a public health measure in prison settings. Although we focused on the EU/EEA, we included studies from other high-income countries to complement the findings.

The search highlighted some important gaps and limitations of the existing evidence. "Most of the existing evidence on active case finding in prison settings are concentrated on a few communicable diseases, namely BBVs, STIs and TB. These findings may be consistent with the general notion that these diseases \[constitute\] a sizeable disease burden in the prison population, and \[that there is\] higher risk of transmission within prison settings \[([@mxy001C8], [@mxy001C10])\]" ([@mxy001C6], p. 32). This review also highlighted a large heterogeneity among studies in the peer-reviewed and gray literature with respect to study setting, design, and population; outcomes of interest; and testing modalities. The few included comparative studies often simultaneously compared different bundles of interventions, making it difficult to disentangle the ones responsible for any observed change in effectiveness. Most of the included studies had an observational design. "Drawing conclusions based on indirect comparisons between studies has serious limitations, as differences in population characteristics, settings, countries, active case finding \[modalities\]...can all influence study outcomes. Most studies did not take confounding or modifying factors, such as the above stated population characteristics, into account....Moreover, these study characteristics as well as interventions and outcomes were frequently poorly described, further hampering these comparisons" ([@mxy001C6], p. 37). In addition, many studies were conducted in single institutions and had relatively small sample sizes. As a result of these limitations, mostly studies of low or very low quality were included in this review. In addition, although we had an EU/EEA focus, most of the studies we retrieved were performed in non--EU/EEA countries, most commonly the United States, including most of the comparative studies, as also reported previously ([@mxy001C13]). The extensive search for EU/EEA-generated gray literature partially counterbalanced the publication bias, although concerns remain over the applicability of evidence from the United States to the European context, because of the diversity in the prison and health care systems as well as in population demographics.

Altogether, based on the reported case detection rates, the retrieved studies point toward a higher prevalence of infection in the prison population of the EU/EEA as compared with general population estimates for the same disease ([@mxy001C9], [@mxy001C106]--[@mxy001C109]). However, important variations in case detection rates were observed across countries and studies. These could be due to different active case finding approaches or "from underlying local epidemiologic patterns and demographic set-up of national and single prison populations"([@mxy001C6], p. 33). Overall, such higher positivity rates provide a valid public health argument to strengthen case finding initiatives in these settings. Viral hepatitis, HIV, and STIs have significant asymptomatic phases of infection, resulting in a sizeable undiagnosed fraction in the population ([@mxy001C110], [@mxy001C111]). Active case finding in prison settings could offer the opportunity to escalate case detection by targeting those likely to be at increased risk, whether this be the entire prison population or specific subgroups, depending on the disease in focus. A stronger rationale may be called upon for TB, whereby the higher prevalence of the disease in prison settings is combined with an increased risk of acquisition during prison stay and an increased probability of active disease to develop if a prisoner is already infected as a result of environmental predisposing factors ([@mxy001C10], [@mxy001C82], [@mxy001C92], [@mxy001C109]).

Scaling up active case finding in prison settings has a strong individual rationale as well. It can provide an opportunity for early detection, if followed by appropriate care, and has been shown to be acceptable for the prison population ([@mxy001C44], [@mxy001C101], [@mxy001C102]). According to international standards, people in prison have the same right to care as those in the community ([@mxy001C3], [@mxy001C112], [@mxy001C113]). In line with this principle and the heightened responsibility a state's government holds for the individuals deprived of their liberty, people in prison are entitled to a medical assessment upon entry, which offers the opportunity to conduct active case finding for several relevant conditions, including communicable diseases ([@mxy001C115]).

Testing individuals at admission or early into their period of incarceration is the most commonly reported approach and the one that is generally associated with higher coverage and uptake, although no studies in this review demonstrated a statistically significant difference between different approaches. Testing at entrance is described for HCV, HIV, syphilis, and TB within a period ranging from a few hours to several days. Performing active case finding as soon as possible after entry into the correctional facility is essential to initiate treatment early, which can, along with appropriate other infection control measures (depending on the specific infection), prevent further transmission within the prison population. However, interpreting the findings is challenging and must take into consideration the different disease-specific priorities, such as rapid and effective infection control in the case of active TB cases. In addition, the emotional and psychological statuses of the individual entering detention need to be taken into full consideration. In particular, the stress factor, the lack of agency, the sense of coercion, and the perception of the surrounding environment may affect the individual's understanding and freedom of choice ([@mxy001C13], [@mxy001C114], [@mxy001C115]). The offer of testing during prison stay has been reported for all covered diseases, with large variation in terms of uptake among studies, but it has been shown to effectively complement testing at entry at least for TB ([@mxy001C73], [@mxy001C116]) and HIV ([@mxy001C48]), and is the only reported approach for chlamydia and gonorrhea testing in the EU/EEA ([@mxy001C76], [@mxy001C78]), with the exception of UK ([@mxy001C117]).

According to our findings, targeted testing was considered as a possible approach mostly for HCV, chlamydia, and gonorrhea. For HCV, the group of interest was primarily people who inject drugs, which is consistent with existing epidemiologic data for this subpopulation ([@mxy001C106], [@mxy001C118]). However, this strategy is subject to implementation challenges related to the assessment of the risks and barriers to individual disclosure, and its effectiveness is limited ([@mxy001C11]). Results of a recent cost-effectiveness study from the United States ([@mxy001C16]), which factored in the provision of direct active antiviral treatment for individuals in need, indicate the universal testing approaches were to be preferred to targeted testing. When considering STIs, age-based testing has been reported in the 2 EU/EEA studies retrieved to date ([@mxy001C76], [@mxy001C78]) and was explored in a few comparative and cost-effectiveness studies from the United States. Although, based on the available low-quality evidence, universal testing resulted in comparatively higher uptake and positivity rates, cost-effectiveness considerations were not necessarily aligned ([@mxy001C89], [@mxy001C91], [@mxy001C96]). Existing guidelines also recommend age-driven testing for chlamydia and gonorrhea ([@mxy001C119]--[@mxy001C121]).

Our search retrieved a limited number of studies that provided comparative analysis of different active case finding modalities, and all were generated in the United States. Despite the general lack of statistically significant data, the results indicated that client-initiated testing invariably leads to lower uptake and lower case detection for all diseases of interest. Among provider-initiated modalities, opt-out was usually associated with higher uptake, although fewer studies investigated this approach. Still, studies comparing case detection rate of routine testing approaches alongside the seroprevalence resulting from serosurveys conducted in the same population provided compelling evidence of the residual undiagnosed fraction ([@mxy001C13]). Importantly, opt-out testing may raise concerns of whether people living in prison may lack self-empowerment and the capability to refuse testing if they so wish, a consideration supported by the findings from a US study ([@mxy001C99]). However, well-constructed and explained nonimposing opt-out based on the principle of informed consent would appear consistent with the obligation of a state government to uphold a person's right to the highest attainable standard of health and associated health care, which might fail with an opt-in approach in an environment that might seem discouraging. Opt-out testing might also be more favorable because it is less subject to stigma and discrimination. Preliminary data from the United Kingdom suggest a near doubling of BBV testing after the introduction of an opt-out testing policy as compared with opt-in testing ([@mxy001C122]). Unfortunately, we found no good data to enable us to describe the effect of opt-out testing on differential offer or uptake of testing among people by age, sex, ethnicity, or other factors like learning disability or mental health. However, work at the member-state level on improving health informatics systems in prisons may provide an opportunity to do so.

Testing methods and education initiatives also influence uptake. Rapid and less-invasive testing methods, such as those not requiring venous blood, increased the willingness to be tested among people in prison ([@mxy001C27], [@mxy001C35]). The introduction of point-of-care testing, the use of dried blood spot to collect capillary blood samples, or the use of chest radiographic screening for TB not only may have a positive influence on the acceptability of active case finding initiatives among the prison population but may have important operational implications. Rapid testing methods would contribute to reducing the proportion of individuals not tested because of interprison mobility or sudden release ([@mxy001C42], [@mxy001C44], [@mxy001C52], [@mxy001C57], [@mxy001C59], [@mxy001C98], [@mxy001C104]) and would possibly increase the likelihood that the individual would receive the results.

Finally, some reflections may be warranted on the difference between testing uptake and testing offer. In settings where active case finding is implemented and testing (opt-in or opt-out) is actively offered to the individual, the coverage of the testing offer may be incomplete or suboptimal. Several factors may contribute to missed opportunities for testing, such as those related to the health care provider (e.g., lack of time, low assessment of risk), the patient (e.g., partial disclosure of risks), and environmental or structural reasons (e.g., lack of supplies, unavailability of testing services, custodial staffing levels). Despite the general lack of findings reported in the included studies, these are factors to be considered and addressed when planning and assessing the effect of active case finding initiatives.

Although early diagnosis has clear advantages, to maximize public health and individual benefits, appropriate follow-up interventions such as prevention measures, treatment, and care need to be implemented in line with the aforementioned principle of equivalence of care. However, relevant health outcomes were not often presented in the included studies. Notification of testing results was seldom reported, with the notable exception of HIV testing. Conversely, treatment initiation was frequently described for STIs and TB, with important variations across countries. Linkage to care after release was hardly reported at all; thus information essential for assessing the medium- to long-term outcomes of active case finding activities in prison settings is not provided.

We could not retrieve any evidence on testing for several communicable diseases (e.g., parasitic diseases) in correctional facilities. Despite this, active case finding might still be relevant. Although we have used a broad search approach (i.e., not limited to specific communicable diseases) and covered several literature databases, it is possible that some relevant articles were missed. For instance, a general search term such as "test" was not included in the search, because this resulted in almost double the number of hits as opposed to using more specific active case finding terms (e.g., rapid test, early test). However, to minimize the possibility of missing relevant articles, we manually checked all references of systematic reviews and meta-analyses for additional articles. Furthermore, although this systematic review was focused on adult people in prisons only, the findings may be valid to design specific testing approaches for young offenders.

In conclusion, the evidence on active case finding in correctional facilities in the EU/EEA is limited and heterogeneous, with no studies providing statistically significant evidence of the clear benefit of any single approach over others. As a result, it is challenging to draw conclusions on the effect of different testing approaches, and more comparative studies would be needed to assess the effectiveness and influence of different active case finding strategies in correctional facilities of the EU/EEA. However, available reports of a high disease detection rate when active case finding is conducted in prison settings highlight the potential impact of such public health interventions. Scale-up of provider-initiated testing in EU/EEA correctional facilities could substantially contribute to reducing the undiagnosed fraction and thus prevent additional disease transmission within the prison setting and in the community at large.

Supplementary Material
======================

###### 

Click here for additional data file.

Authors affiliations: Surveillance and Response Unit, European Centre for Disease Prevention and Control, Solna, Sweden (Lara Tavoschi, Netta Beer, Joana Gomes Dias); Pallas, Health Research and Consultancy B.V., Rotterdam, the Netherlands (Hilde Vroling, Marije Vonk Noordegraaf-Schouten, Anouk Oordt-Speets); Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy (Giordano Madeddu, Sergio Babudieri); Health Without Barriers -- European Federation for Prison Health, Viterbo, Italy (Roberto Monarca); Department of Health & Justice, Public Health England, London, UK (Éamonn O'Moore); and Public Health Unit, European Monitoring Centre on Drugs and Drug Addiction, Lisbon, Portugal (Dagmar Hedrich).

The project was funded by the European Centre for Disease Prevention and Control (ECDC; framework contract number ECDC/2015/028; specific contract number ECD.5855) and is part of a wider joint undertaking with the European Monitoring Centre on Drugs and Drug Addiction to develop European guidance on the prevention of communicable diseases in the prison setting. E.O. was the chair of the ECDC expert panel and wrote on their behalf.

Invaluable inputs were received from the following members of the guidance ad hoc scientific panel: Barbara Janíková, Dr. Viktor Mravcik (Czech Republic); Kristel Kivimets (Estonia); Dr. Fadi Meroueh, Dr. Laurent Michel (France); Prof. Heino Stöver, Peter Wiessner, Dr. Ruth Zimmermann (Germany); Dr. Roberto Ranieri (Italy); Erica Cardoso, Dr. Rui Morgado (Portugal); Dr. Lucia Mihailescu (Romania); Dr. Jose-Manuel Royo (Spain), Stefan Enggist, Prof. Hans Wolff (Switzerland); Prof. Sharon Hutchinson (United Kingdom); Alison Hannah (Penal Reform International); Jan Malinowski (Council of Europe); Dr. Lars Møller (World Health Organization); and Dr. Ehab Salah (United Nations Office on Drugs and Crime).

The authors would like to acknowledge the European Centre for Disease Prevention and Control (ECDC) library and ECDC and European Monitoring Centre on Drugs and Drug Addiction staff who contributed to the project: Dr. Andrew Amato, Dr. Helena de Carvalho Gomes, Dr. Erika Duffell, Teymur Noori, Dr. Anastasia Pharris, Prof. Jan Semenza, Ettore Severi, Dr. Gianfranco Spiteri, Dr. Judit Takacs, Dr. Marieke van der Werf, Linda Montanari, Marica Ferri, and Dr. Liesbeth Vandam. The authors thank the field researchers who contributed to the project: Ruth Gray, Sofia Victoria Casado Hoces, Leon Weichert, and Deborah Iwanikow.

Conflict of interest: none declared.

BBV

:   blood-borne virus

EEA

:   European Economic Area

EU

:   European Union

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

HIV

:   human immunodeficiency virus

LTBI

:   latent tuberculosis infection

STI

:   sexually transmitted infections

TB

:   tuberculosis

[^1]: Abbreviations: EEA, European Economic Area; EU, European Union; HIV, human immunodeficiency virus; NR, not reported.

[^2]: ^a^ The date range was 1980--February 2016 for the Cochrane Database.

[^3]: ^b^ A. Gabbuti, Istituti Penitenziari di Firenze, unpublished data, 2015.

[^4]: Abbreviations: EEA, European Economic Area; EU, European Union; NR, not reported.

[^5]: ^a^ The date range was 1980--February 2016 for the Cochrane Database.

[^6]: Abbreviations: EEA, European Economic Area; EU, European Union; NR, not reported.

[^7]: ^a^ The date range was 1980--February 2016 for the Cochrane Database.
